TY - JOUR T1 - Transcriptome analysis of PBMCs reveals distinct immune response in the asymptomatic and re-detectable positive COVID-19 patients JF - medRxiv DO - 10.1101/2021.03.16.21251286 SP - 2021.03.16.21251286 AU - Jiaqi Zhang AU - Dongzi Lin AU - Kui Li AU - Xiangming Ding AU - Lin Li AU - Yuntao Liu AU - Dongdong Liu AU - Jing Lin AU - Xiangyun Teng AU - Yizhe Li AU - Ming Liu AU - Xiaodan Wang AU - Dan He AU - Yaling Shi AU - Dawei Wang AU - Jianhua Xu Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/24/2021.03.16.21251286.abstract N2 - The existence of asymptomatic and re-detectable positive COVID-19 patients presents the disease control challenges of COVID-19. Most studies on immune response of COVID-19 have focused on the moderately or severely symptomatic patients, however little is known about the immune response in asymptomatic and re-detectable positive patients. Here we performed a comprehensive analysis of the transcriptomic profiles of PBMCs from 48 COVID-19 patients which include 8 asymptomatic, 13 symptomatic, 15 recovering and 12 RP patients. Our analysis revealed a down-regulation of IFN response and complement activation in the asymptomatic patients compared with the symptomatic, indicating a weaker immune response of the PBMCs in the asymptomatic patients. In addition, we observed a lower expression of the cytokines and chemokines in the PBMC of asymptomatic and symptomatic patients. In contrast, the cytokines and chemokines level in the RP patients are higher than the recovering. GSEA analysis showed the enrichment of TNFa/NF-κB and influenza infection in the RP patients compared with the recovering patients, indicating a flu-like, hyper-inflammatory immune response in the PBMC of RP patients. Thus our findings could extend our understanding of host immune response during the progression COVID-19 disease and help the clinical management and the immunotherapy development for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Science and Technology Innovation Project of Foshan Municipality (2020001000431) and the National Key Research and Development Project (2020YFA0708001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all participants enrolled in this study. From March and May in 2020, 48 patients with confirmed SARS-CoV-2 admitted to Guangzhou Eighth People's Hospital, Shunde Hospital of Guangzhou University of Chinese Medicine, Fourth People's Hospital of Foshan, and First People's Hospital of Foshan, were enrolled in this study. This study was reviewed and approved by the ethics committees of the above four participant hospitals.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing is not applicable to this article as no new data were created or analyzed in this study. ER -